These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 14140000

  • 1. EFFECT OF DOSAGE FORM PROPERTIES ON THERAPEUTIC EFFICACY OF TOLBUTAMIDE TABLETS.
    LEVY G.
    Can Med Assoc J; 1964 Apr 18; 90(16):978-9. PubMed ID: 14140000
    [Abstract] [Full Text] [Related]

  • 2. RATES OF DISSOLUTION OF TOLBUTAMIDE TABLETS.
    BRUDNEY N, STEWART DJ, EUSTACE BT.
    Can Med Assoc J; 1964 Apr 18; 90(16):980-1. PubMed ID: 14140001
    [Abstract] [Full Text] [Related]

  • 3. A dissolution rate apparatus for the prediction of initial drug absorption patterns in beagles: tolbutamide tablets.
    Simmons DL, Legore AA, Picotte P, Lee KS, Joshi NN.
    J Pharmacokinet Biopharm; 1975 Feb 18; 3(1):39-49. PubMed ID: 1127577
    [Abstract] [Full Text] [Related]

  • 4. Drug dissolution: significance of physicochemical properties and physiological conditions.
    Jambhekar SS, Breen PJ.
    Drug Discov Today; 2013 Dec 18; 18(23-24):1173-84. PubMed ID: 24042023
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations.
    Aghazadeh-Habashi A, Jamali F.
    Eur J Pharm Biopharm; 2008 Nov 18; 70(3):889-94. PubMed ID: 18715548
    [Abstract] [Full Text] [Related]

  • 6. Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389.
    Badawy SI, Gray DB, Zhao F, Sun D, Schuster AE, Hussain MA.
    Pharm Res; 2006 May 18; 23(5):989-96. PubMed ID: 16715389
    [Abstract] [Full Text] [Related]

  • 7. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y, Takeuchi S, Matsui K, Amidon GE, Amidon GL.
    Eur J Pharm Sci; 2015 Aug 30; 76():203-12. PubMed ID: 25978875
    [Abstract] [Full Text] [Related]

  • 8. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A, Blume H, Dressman J.
    Eur J Pharm Biopharm; 2013 Nov 30; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [Abstract] [Full Text] [Related]

  • 9. A COMPARATIVE STUDY OF SOME BRANDS OF TOLBUTAMIDE AVAILABLE IN CANADA. II. PHARMACEUTICAL ASPECTS.
    LU FC, RICE WB, MAINVILLE CW.
    Can Med Assoc J; 1965 May 29; 92(22):1166-9. PubMed ID: 14289147
    [Abstract] [Full Text] [Related]

  • 10. Eudraginated polymer blends: a potential oral controlled drug delivery system for theophylline.
    Emeje M, John-Africa L, Isimi Y, Kunle O, Ofoefule S.
    Acta Pharm; 2012 Mar 29; 62(1):71-82. PubMed ID: 22472450
    [Abstract] [Full Text] [Related]

  • 11. [Influence of formulation of enterosoluble preparations on the physiologic disposition of the active principle. Part III. Establishment of quantitative correlations between the rate of dissolution in vitro of the active principle and its absorption characteristics].
    Delporte JP.
    J Pharm Belg; 1976 Mar 29; 31(2):150-68. PubMed ID: 950582
    [No Abstract] [Full Text] [Related]

  • 12. Generic tolbutamide tablet dissolution: intralot and interlot variation.
    Ayres JW, Huang HP, Albert K.
    J Pharm Sci; 1984 Nov 29; 73(11):1629-34. PubMed ID: 6520768
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E, Prakongpan S, Amidon GL, Dressman JB.
    Clin Pharmacokinet; 2006 Nov 29; 45(4):385-99. PubMed ID: 16584285
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of Dissolution in the Lower Intestine and Its Impact on the Absorption Process of High Dose Low Solubility Drugs.
    Georgaka D, Butler J, Kesisoglou F, Reppas C, Vertzoni M.
    Mol Pharm; 2017 Dec 04; 14(12):4181-4191. PubMed ID: 28366005
    [Abstract] [Full Text] [Related]

  • 16. Lot-to-lot variation in dissolution of tolbutamide tablets.
    Ayres JW.
    Am J Hosp Pharm; 1980 Oct 04; 37(10):1329-32. PubMed ID: 7424928
    [Abstract] [Full Text] [Related]

  • 17. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH, Shin S, Bulitta JB, Youn YS, Yoo SD, Shin BS.
    Mol Pharm; 2017 Jan 03; 14(1):53-65. PubMed ID: 27809538
    [Abstract] [Full Text] [Related]

  • 18. Considerations in the development of an in vitro dissolution condition for lacidipine tablets: in vivo pharmacokinetic evaluation.
    Sun M, Sun J, He S, Wang Y, Sun Y, Liu X, He Z.
    Drug Dev Ind Pharm; 2012 Sep 03; 38(9):1099-106. PubMed ID: 22188158
    [Abstract] [Full Text] [Related]

  • 19. Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity.
    Radwan A, Amidon GL, Langguth P.
    Biopharm Drug Dispos; 2012 Oct 03; 33(7):403-16. PubMed ID: 22782559
    [Abstract] [Full Text] [Related]

  • 20. In vitro--in silico--in vivo drug absorption model development based on mechanistic gastrointestinal simulation and artificial neural networks: nifedipine osmotic release tablets case study.
    Ilić M, Ðuriš J, Kovačević I, Ibrić S, Parojčić J.
    Eur J Pharm Sci; 2014 Oct 01; 62():212-8. PubMed ID: 24911992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.